CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Grants and contracts	$ 1,138,187	$ 1,948,362
Operating expenses:
Research and development	3,619,103	5,048,423
General and administrative	2,318,990	2,500,749
Total operating expenses	5,938,093	7,549,172
Loss from operations	(4,799,906)	(5,600,810)
Other income (expense):
Interest and other income	126,127	197,766
Foreign exchange gain (loss)	3,514	(13,482)
Change in value of warrant liability	962,818	(4,426,146)
Total other income (expense)	1,092,459	(4,241,862)
Net loss	(3,707,447)	(9,842,672)
Net loss attributable to noncontrolling interests	(95,474)	(136,216)
Net loss attributable to Cleveland BioLabs, Inc.	$ (3,611,973)	$ (9,706,456)
Net loss available to common stockholders per share of common stock, basic and diluted (per share)	$ (0.32)	$ (0.87)
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted (shares)	11,293,842	11,192,435